NCT01769781

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide).

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy · Network
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

Detailed description

Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing recurrence after surgery at least in 20-50% after 5 years of follow-up. Aromatase inhibitor plus GnRH analog may be more effective than GnRH agonist alone in the treatment of endometriosis recurrence.

Conditions

• Endometriosis

Interventions

Type	Name	Description
DRUG	anastrazole	combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
DRUG	GnRH analog alone	treatment for three months with GnRH analog (leuprolide acetate) alone

Timeline

• Start date: 2013-01-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2013-01-17
• Last updated: 2016-04-27

Locations

1 site across 1 country: Italy